The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of forcing insulin prices to skyrocket since 2012. The Federal Trade Commission claims that the middlemen — known as pharmacy benefit managers,

Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin.

The Federal Trade Commission on Friday filed a lawsuit over insulin prices against the three largest pharmaceutical middlemen that negotiate prescription drug prices, arguing that the companies artificially inflate the costs of the lifesaving diabetes drug for patients.